Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare Co., Ltd. is a biotechnology and pharmaceutical company based in Taipei, Taiwan, specializing in the research, development, and manufacture of innovative medical products. Established in 2001, the company focuses primarily on therapeutic solutions involving hyaluronic acid, delivering both drugs and medical devices for clinical use. Its core offerings include injectable treatments for osteoarthritis and soft tissue injuries, as well as oral medications such as hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Notably, Holy Stone Healthcare also develops advanced diagnostic reagents for latent tuberculosis infection and is engaged in the R&D of new medicines targeting conditions like ulcerative colitis, colorectal cancer, Alzheimer’s disease, and various lymphatic and hematological disorders. Its products serve both domestic and international medical markets. Through continuous innovation and specialization in biopharmaceuticals, Holy Stone Healthcare Co., Ltd. plays a significant role in advancing treatment options within the broader health technology sector, contributing to the ongoing evolution of therapeutic practices and patient care standards in East Asia and beyond.